盆腔炎后不孕 中国就医指南

Infertility following pelvic inflammatory disease (PID) is a common complication of untreated or inadequately treated upper genital tract infection in women, characterized by impaired ability to conceive naturally due to structural and functional damage to the fallopian tubes, ovaries, and uterine environment. PID—typically caused by ascending infections with *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, or polymicrobial anaerobic/aerobic flora—triggers chronic inflammation, tubal scarring, hydrosalpinx formation, adhesions, and endometrial dysfunction. Pathogenesis involves direct mucosal injury, fibroblast activation, and aberrant tissue remodeling, leading to tubal occlusion (in up to 15–20% after one episode), ciliary dysfunction, and impaired embryo transport. Epidemiologically, PID affects an estimated 1–2 million women annually in the U.S., with global incidence highest in low-resource settings and among adolescents and young adults aged 15–24. Up to 10–20% of women with a single documented PID episode develop infertility; risk rises to 40–60% after three or more episodes. Key modifiable risk factors include unprotected intercourse with multiple partners, delayed diagnosis or treatment, prior history of STIs, douching, and intrauterine device (IUD) insertion during active cervicitis. Non-modifiable risks include younger age at first infection and genetic susceptibility to inflammatory dysregulation. Beyond reproductive consequences, this condition significantly impairs quality of life: patients report elevated rates of anxiety, depression, marital strain, social stigma, and diminished sexual self-esteem. Many experience prolonged diagnostic odysseys, financial stress from repeated fertility evaluations, and emotional exhaustion from failed conception attempts. Unlike primary ovarian insufficiency or male-factor infertility, PID-related infertility often presents without overt symptoms post-infection—making early recognition of subtle signs (e.g., chronic pelvic pain, irregular bleeding, painful intercourse) critical for timely intervention. Fertility preservation strategies—including prompt antibiotic stewardship, surgical adhesiolysis, and assisted reproductive technologies—are most effective when initiated before irreversible tubal damage occurs. Multidisciplinary care involving reproductive endocrinologists, infectious disease specialists, and mental health professionals is essential to address both biological and psychosocial dimensions.

# 盆腔炎后不孕治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：轻中度输卵管粘连、盆腔轻度积水、无明显解剖阻塞者，AMH≥1.2 ng/mL，年龄＜35岁。

• •药物治疗：抗生素（多西环素+甲硝唑）+ 中药灌肠（丹参注射液+红藤汤）+ GnRH-a降调（3个月）

• •物理治疗：短波理疗+盆底生物反馈（12次）

• •基础检查费（必查）：阴道超声、性激素六项、AMH、衣原体/支原体培养、输卵管造影（HSG）

二、手术/微创介入方案

适用人群：HSG或腹腔镜证实输卵管伞端粘连、中度积水、盆腔广泛粘连；保守治疗6个月未孕者。

• •宫腹腔镜联合松解术+输卵管整形术（含CO₂气腹、高清摄像系统、可吸收缝线）

• •术前检查费（含增强盆腔MRI、心电图、血栓风险评估、术前感染筛查）：¥2,360–¥3,120

三、特殊复杂方案

适用人群：双侧输卵管严重闭锁/切除术后、合并重度子宫内膜异位症（rAFS IV期）、反复盆腔脓肿史或耐药菌感染者。

• •IVF-ET助孕（含促排卵+胚胎移植+冷冻保存）：首周期总费用 ¥32,000–¥48,000（不含多次移植）
• •输卵管切除+IVF前预处理（如腹腔镜卵巢打孔+抗炎疗程）：额外增加 ¥12,000–¥16,000

四、方案快速选择指南

• •预算≤¥1万/年 + 年龄＜32岁 + 输卵管通畅 → 首选保守治疗
• •预算¥2–3万 + 输卵管部分通畅 + AMH≥1.0 → 宫腹腔镜联合手术
• •预算≥¥3.5万 + 双侧阻塞/切除/高龄（≥35岁） → 直接IVF-ET
• •合并脓肿/耐药菌/复发性盆腔痛 → 先行感染控制+个体化IVF路径